Primary central nervous system lymphoma: Difference between revisions
Line 21: | Line 21: | ||
==[[Primary central nervous system lymphoma other diagnostic studies|Other Diagnostic Studies]]== | ==[[Primary central nervous system lymphoma other diagnostic studies|Other Diagnostic Studies]]== | ||
==Treatment== | ==Treatment== |
Revision as of 18:51, 21 January 2012
Template:DiseaseDisorder infobox
Primary central nervous system lymphoma Microchapters |
Differentiating Primary Central Nervous System Lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Primary central nervous system lymphoma On the Web |
American Roentgen Ray Society Images of Primary central nervous system lymphoma |
Directions to Hospitals Treating Primary central nervous system lymphoma |
Risk calculators and risk factors for Primary central nervous system lymphoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Classification
History & Symptoms
Diagnosis
MRI
CT
Other Diagnostic Studies
Treatment
Medical Therapy
Surgical resection is usually ineffective because of the depth of the tumor. Treatment with irradiation and corticosteroids often only produces a partial response, but tumor recurs in more than 90% of patients. Median survival is 10 to 18 months in immunocompetent patients, and less in those with AIDS. The addition of IV methotrexate and citrovorum may extend survival to a median of 3.5 years. If radiation is added to methotrexate, median survival may increase beyond 4 years. However, radiation is not recommended in conjunction with methotrexate because of increased risk of leukoencephalopathy and dementia in patients older than 60 years of age[1].
References
- ↑ Deangelis LM, Hormigo A. Treatment of primary central nervous system lymphoma. Semin Oncol 2004; 31:684-692. In AIDS patients, perhaps the most important factor with respect to treatment is the use of highly active anti-retroviral therapy (HAART), which affects the CD4+ lymphocyte population and the level of immunosuppression